Pathways' Pick of the Week: AdvaMed’s AI Takes

article image

AdvaMed sends AI policy priorities to Capitol Hill. Excerpted from Pathways’ Picks May 15: AI Activity, EU Priorities, China Classifications, and More.

In March, a US lawmaker issued a “request for information” about gaps and opportunities regarding the use of artificial intelligence in healthcare, and dozens of organizations, including the American Hospital Association and an array of clinical groups, responded last week before the May 6 deadline. Among the most detailed responses to Rep. Ami Bera’s (D-CA) request, however, came from AdvaMed, which submitted a 22-page set of recommendations for AI. The trade group gave the most detailed attention to reimbursement issues. In particular, it emphasized areas where Congress can encourage CMS to modernize its regulatory structure for AI, including by aligning Medicare benefit categories with AI/machine learning technologies and rethinking the assumptions of its payments systems (Physician Fee Scheduleoutpatient, etc.) in the context of AI.

AdvaMed also used its response to press FDA to allow more flexibility in how it applies predetermined change control plans for AI/ML devices. Further, it pushed for a more cohesive, national approach to balancing the use of health data to support AI and ensuring patient protections. “Current laws, policies, and regulations do not adequately address privacy and ethical risks and allow for the best use of patient health data,” the group wrote. “Assembling an optimal framework for the regulation and oversight of data used in AI models for healthcare needs true innovation, boldness, and originality.” Some other specific proposals included in AdvaMed’s letter:

  • Incentive payments to hospitals to implement AI technologies similar to existing incentives to adopt electronic health records
  • Expanding FDA’s authority to permit electronic labeling in lieu of paper labeling for devices
  • Legislative solutions to address the impact of “budget neutrality constraints on coverage and adoption of AI technologies”
Continue reading Pathways’ Picks here.



Articles from David Filmore:

Regulatory & Reimbursement

EU Elections, Medicare Picks, Lab Lawsuit, and More

In this week’s Pathways Picks: Important inflection points for future medtech regulatory reforms with EU Parliament elections and a notable committee hearing in Germany; US lawmakers press CMS on digital therapeutics reimbursement; lab industry follows through on LDT lawsuit; FDA completes reorganization; Brazil regulatory agencies face budget cuts; and more from the US, Europe, and China.

Read Article